The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 09, 2022

Filed:

May. 20, 2020
Applicants:

The Texas A&m University System, College Station, TX (US);

Università Degli Studi Di Pavia, Pavia, IT;

Technische Universität Braunschweig, Braunschweig, DE;

Inventors:

Ya-Ping Ko, Sugar Land, TX (US);

Magnus Hook, Houston, TX (US);

Srishtee Arora, Houston, TX (US);

Livia Visai, Rosate, IT;

Federico Bertoglio, Spinadesco, IT;

Michael Hust, Braunschweig, DE;

Doris Meier, Andreasberg, DE;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/085 (2006.01); C07K 16/12 (2006.01); A61K 47/68 (2017.01);
U.S. Cl.
CPC ...
C07K 16/1271 (2013.01); A61K 39/085 (2013.01); A61K 47/6803 (2017.08); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01);
Abstract

The present disclosure provides methods and composition including vaccines, monoclonal antibodies, polyclonal antibodies, chimeric molecule of an extracellular fibrinogen binding protein (Efb) and targeted agent delivery pharmaceutical composition comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in inhibiting the fibrinogen binding, C3 binding, or both or administering to a subject a pharmacologically effective amount of a vaccine in a pharmaceutically acceptable excipient, comprising a modified extracellular fibrinogen binding protein comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in not shielding the staphylococcus bacterium from recognition by a phagocytic receptor.


Find Patent Forward Citations

Loading…